
Ravi P Shah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5859814/publications.pdf Version: 2024-02-01



<u>Ρλνι Ρ </u>

#	Article	IF	CITATIONS
1	A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2012, 69, 148-173.	2.8	166
2	Critical practical aspects in the application of liquid chromatography–mass spectrometric studies for the characterization of impurities and degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2014, 87, 191-217.	2.8	77
3	Identification and characterization of degradation products of irbesartan using LC–MS/TOF, MSn, on-line H/D exchange and LC–NMR. Journal of Pharmaceutical and Biomedical Analysis, 2010, 51, 1037-1046.	2.8	55
4	Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products. Rapid Communications in Mass Spectrometry, 2008, 22, 613-622.	1.5	47
5	LC and LC–MS/TOF studies on stress degradation behaviour of candesartan cilexetil. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 345-354.	2.8	35
6	Identification and characterization of a photolytic degradation product of telmisartan using LC–MS/TOF, LC–MSn, LC–NMR and on-line H/D exchange mass studies. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 755-761.	2.8	24
7	Stress degradation studies on lornoxicam using LC, LC–MS/TOF and LC–MSn. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 538-545.	2.8	24
8	LC-MS/TOF, LC-MSn, on-line H/D exchange and LC-NMR studies on rosuvastatin degradation and in silico determination of toxicity of its degradation products: a comprehensive approach during drug development. Analytical and Bioanalytical Chemistry, 2013, 405, 3215-3231.	3.7	24
9	Strategy for identification and characterization of small quantities of drug degradation products using LC and LCâ€MS: Application to valsartan, a model drug. Drug Testing and Analysis, 2010, 2, 82-90.	2.6	23
10	Amalgamation of stress degradation and metabolite profiling in rat urine and feces for characterization of oxidative metabolites of flibanserin using UHPLC-Q-TOF-MS/MS, H/D exchange and NMR technique. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1139, 121993.	2.3	18
11	Practical and Economical Implementation of Online H/D Exchange in LC-MS. Analytical Chemistry, 2013, 85, 10904-10912.	6.5	14
12	A mechanistic explanation on degradation behavior of flibanserin for identification and characterization of its potential degradants using LC-DAD/ESI/APCI-Q-TOF-MS/MS. Microchemical Journal, 2021, 167, 106281.	4.5	11
13	LC and LC-HRMS studies on stability behavior of molnupiravir an anti-COVID 19 drug. Journal of Liquid Chromatography and Related Technologies, 2021, 44, 750-759.	1.0	9
14	Exploring unexplored biomarkers of oxidative distress and their use. Advances in Redox Research, 2021, 3, 100020.	2.1	4
15	A systematic UHPLC-Q-TOF-MS/MS based analytical approach for characterization of flibanserin metabolites and establishment of biotransformation pathway. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1185, 123011.	2.3	2
16	LC-HRMS studies on ruxolitinib degradation: a comprehensive approach during drug development. Analytical Methods, 2022, 14, 480-490.	2.7	2
17	Synthetic pharmaceutical peptides characterization by chromatography principles and method development. Journal of Separation Science, 2022, 45, 2200-2216.	2.5	2